Company Announcement - EyePoint Pharmaceuticals appoints Dr Reginald J Sanders to its Board of Directors [1] - Dr Sanders is a distinguished leader in ophthalmology with extensive experience in retina research and business development [2] - Dr Sanders has served as President of the American Society of Retina Specialists and is a board member of Prism Vision Group [2] - Dr Sanders has over 50 publications and has been a principal investigator for landmark treatments like Lucentis [2] - Dr Sanders has received numerous honors including induction into the Retina Hall of Fame and the Packo Service Award [3] Clinical Development - EyePoint's lead product candidate DURAVYU is in Phase 3 global pivotal trials for wet AMD and Phase 2 trials for diabetic macular edema [4] - Topline data from the Phase 2 trial in diabetic macular edema is expected in Q1 2025 [4] - Topline data from both Phase 3 pivotal trials in wet AMD is expected in 2026 [4] - EyePoint's pipeline includes EYP-2301 a TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases [5] Technology and Partnerships - EyePoint leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [4] - Vorolanib used in DURAVYU is licensed exclusively by Equinox Sciences for ophthalmic diseases outside of China Macao Hong Kong and Taiwan [6] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901 [6]

WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET. A webcast and subseque ...

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expres ...

Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.56 indicates a potential upside of 175.1%.The average comprises nine short-term price targets ranging from a low of $18 to a high of $68, with a standard deviation of $15.13. While the lowest estimat ...

Revenue Performance - Product sales, net decreased by $0.2 million (19%) to $0.7 million for Q3 2024 compared to Q3 2023, driven by lower YUTIQ® sales to ANI[115] - License and collaboration agreement revenue decreased by $4.6 million (32%) to $9.6 million for Q3 2024 due to lower recognition of deferred revenue from YUTIQ® licensing to ANI[116] - Total revenues decreased by $4.7 million (31%) to $10.5 million for Q3 2024 compared to Q3 2023[114] - Product sales, net decreased by $11.1 million, or 82%, to $2.4 million for the nine months ended September 30, 2024, driven by the agreement granting YUTIQ® license and rights to ANI[124] - License and collaboration agreement revenue increased by $10.1 million, or 57%, to $27.9 million for the nine months ended September 30, 2024, due to higher recognition of deferred revenue[125] Expenses and Costs - Research and development expenses increased by $12.2 million (70%) to $29.5 million for Q3 2024[114] - Research and development expenses increased by $12.2 million, or 70%, to $29.5 million for the three months ended September 30, 2024, driven by higher clinical trial costs and personnel expenses[119] - Research and development expenses increased by $42.8 million, or 92%, to $89.6 million for the nine months ended September 30, 2024, driven by higher clinical trial costs and personnel expenses[128] - Cost of sales decreased by $0.5 million, or 39%, to $0.7 million for the three months ended September 30, 2024, primarily due to lower commercial product sales[118] - Sales and marketing expenses decreased by $0.5 million, or 95%, for the three months ended September 30, 2024, due to discontinued YUTIQ® promotion and exit from the commercial business[120] - General and administrative expenses increased by $2.4 million, or 23%, to $13.0 million for the three months ended September 30, 2024, primarily due to higher stock-based compensation and personnel costs[121] Net Loss and Financial Performance - Net loss increased by $16.7 million (133%) to $29.4 million for Q3 2024 compared to Q3 2023[114] - Net cash used in operating activities for the nine months ended September 30, 2024 totaled $90.4 million, primarily due to a net loss of $89.5 million, reduced by $25.8 million of non-cash expenses[139] - Operating cash inflows for the nine months ended September 30, 2023 totaled $25.0 million, primarily due to a net loss of $56.7 million reduced by $10.5 million of non-cash expenses[140] Royalty and Interest Income - Royalty income increased by $0.05 million (20%) to $0.3 million for Q3 2024, attributed to higher non-cash Alimera royalties payable to SWK Funding LLC[117] - Interest income increased by $1.6 million, or 90%, to $3.4 million for the three months ended September 30, 2024, due to higher cash and marketable securities[122] - Interest income increased by $6.5 million, or 142%, to $11.1 million for the nine months ended September 30, 2024, due to higher cash and marketable securities and interest rates[131] Clinical Trials and Product Development - DURAVYU™ 2.7mg demonstrated a gain of +8.9 letters in BCVA and CST improvement of 68.1 microns in the Phase 2 VERONA trial for DME[110] - The company expects to report full topline results for the Phase 2 VERONA trial of DURAVYU™ for DME in Q1 2025[110] Financing and Capital Activities - The company completed a $161.0 million public offering in October 2024, selling 14,636,363 shares at $11.00 per share[109] - Net cash provided by financing activities for the nine months ended September 30, 2024 totaled $12.3 million, including $11.8 million from the issuance of Common Stock and $5.4 million from the exercise of stock options[142] - Net cash used in financing activities for the nine months ended September 30, 2023 totaled $31.4 million, including $40.5 million used to pay off the SVB loan[142] Manufacturing and Facilities - The company opened a 40,000 square foot cGMP-compliant manufacturing facility in Northbridge, MA in October 2024[109] Cash and Investments - The company had cash, cash equivalents, and investments in marketable securities of $253.8 million as of September 30, 2024, and expects to fund operations into 2027[135] - Net cash used in investing activities for the nine months ended September 30, 2024 totaled $123.4 million, including $119.7 million for the purchase of marketable securities and $3.7 million for property and equipment[141] Working Capital and Non-Cash Expenses - Changes in working capital for the nine months ended September 30, 2024 included $26.7 million, with $22.1 million related to deferred revenue from the YUTIQ product rights license agreement[139] - Changes in working capital for the nine months ended September 30, 2023 included $71.2 million, with $57.4 million related to deferred revenue from the YUTIQ product rights license agreement[140] - Non-cash expenses for the nine months ended September 30, 2024 included $28.8 million of stock-based compensation[139] - Non-cash expenses for the nine months ended September 30, 2023 included $8.5 million of stock-based compensation and $1.3 million of loss on extinguishment of debt[140] Regulatory and Reporting - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[143]

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.55 per share when it actually produced a loss of $0.58, delivering a surprise of -5.45%.Over the last four ...

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 14,636,363 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock, at the publi ...

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has announced a public offering of 12,727,273 shares at a price of $11.00 per share, aiming to raise approximately $140.0 million before expenses [1][2]. Group 1: Offering Details - The offering consists of common stock sold entirely by EyePoint, with the closing expected around October 31, 2024, pending customary conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,909,090 shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be utilized to advance clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as support earlier stage pipeline initiatives and general corporate purposes [2]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, leveraging its proprietary Durasert E™ technology for sustained intraocular drug delivery [6][7]. - The lead product candidate, DURAVYU™, is currently in Phase 3 trials for wet AMD and Phase 2 trials for DME, with topline data expected in Q1 2025 and 2026 respectively [6][8].

EyePoint Pharmaceuticals (EYPT) shares soared 27.6% in the last trading session to close at $12.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.1% gain over the past four weeks. Earlier this week, the company announced positive interim 16-week data from the ongoing phase II VERONA study evaluating its lead pipeline candidate, Duravyu, for treating patients with diabetic macular edema. Recently, EyePoint Pharmaceuticals als ...

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has initiated a public offering of $100 million in common stock to support its clinical development and pipeline initiatives [1][3]. Group 1: Offering Details - The public offering consists of $100 million in shares, with an option for underwriters to purchase an additional $15 million within 30 days [1][2]. - J.P. Morgan, Citigroup, and Guggenheim Securities are the joint book running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [3]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, leveraging its proprietary Durasert E™ technology for sustained intraocular drug delivery [7][8]. - The lead product candidate, DURAVYU™, is currently in Phase 3 clinical trials for wet AMD and Phase 2 trials for DME, with topline data expected in Q1 2025 and 2026 respectively [7][8].